See more : DDH1 Limited (DDHLF) Income Statement Analysis – Financial Results
Complete financial analysis of Newron Pharmaceuticals S.p.A. (NWPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Newron Pharmaceuticals S.p.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Property Agent Inc. (3464.T) Income Statement Analysis – Financial Results
- Orange Minerals NL (OMX.AX) Income Statement Analysis – Financial Results
- Twinlab Consolidated Holdings, Inc. (TLCC) Income Statement Analysis – Financial Results
- Sagalio Energy Limited (SAN.AX) Income Statement Analysis – Financial Results
- The Chiba Bank, Ltd. (CHBAF) Income Statement Analysis – Financial Results
Newron Pharmaceuticals S.p.A. (NWPHF)
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
Newron TRS Study 6 Months' Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria
Source: https://incomestatements.info
Category: Stock Reports